20150288 A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Blinatumomab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Sponsors Amgen
- 31 Aug 2018 Biomarkers information updated
- 02 Aug 2018 Planned End Date changed from 23 Feb 2020 to 15 Nov 2019.
- 02 Aug 2018 Planned primary completion date changed from 6 Jun 2019 to 4 Apr 2019.